- Home
- FT vs VTYX Comparison
FT vs VTYX Comparison
Compare FT & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- VTYX
- Stock Information
- Founded
- FT 1988
- VTYX 2018
- Country
- FT United States
- VTYX United States
- Employees
- FT N/A
- VTYX N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- FT Finance
- VTYX Health Care
- Exchange
- FT Nasdaq
- VTYX Nasdaq
- Market Cap
- FT 189.6M
- VTYX 184.6M
- IPO Year
- FT N/A
- VTYX 2021
- Fundamental
- Price
- FT $7.28
- VTYX $2.30
- Analyst Decision
- FT
- VTYX Buy
- Analyst Count
- FT 0
- VTYX 5
- Target Price
- FT N/A
- VTYX $8.40
- AVG Volume (30 Days)
- FT 63.0K
- VTYX 2.3M
- Earning Date
- FT 01-01-0001
- VTYX 11-07-2024
- Dividend Yield
- FT 7.85%
- VTYX N/A
- EPS Growth
- FT N/A
- VTYX N/A
- EPS
- FT N/A
- VTYX N/A
- Revenue
- FT N/A
- VTYX N/A
- Revenue This Year
- FT N/A
- VTYX N/A
- Revenue Next Year
- FT N/A
- VTYX N/A
- P/E Ratio
- FT N/A
- VTYX N/A
- Revenue Growth
- FT N/A
- VTYX N/A
- 52 Week Low
- FT $5.97
- VTYX $1.67
- 52 Week High
- FT $7.23
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- FT 20.83
- VTYX 47.68
- Support Level
- FT $7.59
- VTYX $2.21
- Resistance Level
- FT $7.78
- VTYX $2.54
- Average True Range (ATR)
- FT 0.12
- VTYX 0.27
- MACD
- FT -0.06
- VTYX -0.05
- Stochastic Oscillator
- FT 8.00
- VTYX 8.02
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.